source
- Experts see bispecific antibodies and CAR-T therapies emerging as future options beyond BTK inhibitors for mantle cell lymphomaLore Gruenbaum, PhD, chief scientific officer and senior vice president of research at Blood Cancer United, discussed alternative treatment strategies for mantle cell lymphoma (MCL) that go beyond…
- Phase 2 interim data show rezatapopt yields meaningful responses in heavily pretreated ovarian cancer patients with TP53 Y220C mutationAlison Schram, MD presented interim results from the PYNNACLE Phase 2 trial of rezatapopt, a selective p53 reactivator, in patients whose tumors carry the TP53 Y220C mutation. The analysis focused…